| scholarly article | Q13442814 |
| P2093 | author name string | Li Zhang | |
| Wei Li | |||
| Jie Wang | |||
| Gang Cheng | |||
| Caicun Zhou | |||
| Cheng-Ping Hu | |||
| Jifeng Feng | |||
| Shun Lu | |||
| Shukui Qin | |||
| Barbara Peil | |||
| Agnieszka Cseh | |||
| Neil Gibson | |||
| Eva Ehrnrooth | |||
| P2860 | cites work | Prevention and management of lung cancer in China | Q26786585 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | Q27853359 | ||
| The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials | Q56562737 | ||
| Prevalence of smoking in China in 2010 | Q84419789 | ||
| Comprehensive genomic characterization of squamous cell lung cancers | Q28274701 | ||
| Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship | Q28278682 | ||
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib | Q33704088 | ||
| Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | Q34662482 | ||
| The impact of tobacco on lung health in China | Q35175986 | ||
| Epidemiology of lung cancer in China | Q35663602 | ||
| Cancer patient preferences for quality and length of life | Q37023256 | ||
| Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). | Q37126929 | ||
| The incidence and mortality of major cancers in China, 2012. | Q37148344 | ||
| The International Epidemiology of Lung Cancer: geographical distribution and secular trends. | Q37231659 | ||
| The clinicopathological and prognostic features of Chinese and Japanese inpatients with lung cancer | Q37687179 | ||
| Diarrhea associated with afatinib: an oral ErbB family blocker | Q38090739 | ||
| Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. | Q38385682 | ||
| Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial | Q38544205 | ||
| Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward? | Q38549559 | ||
| Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy | Q38669314 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Q40408396 | ||
| Estimates of cancer incidence in China for 2000 and projections for 2005. | Q40451705 | ||
| Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value | Q41443083 | ||
| Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer | Q48662294 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erlotinib | Q418369 |
| squamous cell carcinoma of the lung | Q5749020 | ||
| P304 | page(s) | 8565-8573 | |
| P577 | publication date | 2018-11-30 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung | |
| P478 | volume | 11 |
| Q64114283 | Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib | cites work | P2860 |
Search more.